244 related articles for article (PubMed ID: 17682989)
1. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis.
Catanzaro A; Cloud GA; Stevens DA; Levine BE; Williams PL; Johnson RH; Rendon A; Mirels LF; Lutz JE; Holloway M; Galgiani JN
Clin Infect Dis; 2007 Sep; 45(5):562-8. PubMed ID: 17682989
[TBL] [Abstract][Full Text] [Related]
2. Refractory coccidioidomycosis treated with posaconazole.
Anstead GM; Corcoran G; Lewis J; Berg D; Graybill JR
Clin Infect Dis; 2005 Jun; 40(12):1770-6. PubMed ID: 15909265
[TBL] [Abstract][Full Text] [Related]
3. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis.
Ampel NM; Giblin A; Mourani JP; Galgiani JN
Clin Infect Dis; 2009 Jan; 48(2):172-8. PubMed ID: 19072555
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole therapy for chronic refractory coccidioidomycosis.
Stevens DA; Rendon A; Gaona-Flores V; Catanzaro A; Anstead GM; Pedicone L; Graybill JR
Chest; 2007 Sep; 132(3):952-8. PubMed ID: 17573510
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole.
Kim MM; Vikram HR; Kusne S; Seville MT; Blair JE
Clin Infect Dis; 2011 Dec; 53(11):1060-6. PubMed ID: 22045955
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.
Moton A; Krishna G; Wang Z
J Clin Pharm Ther; 2009 Jun; 34(3):301-11. PubMed ID: 19646076
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
Chishimba L; Niven RM; Cooley J; Denning DW
J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
[TBL] [Abstract][Full Text] [Related]
9. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
11. Activity of posaconazole in the treatment of central nervous system fungal infections.
Pitisuttithum P; Negroni R; Graybill JR; Bustamante B; Pappas P; Chapman S; Hare RS; Hardalo CJ
J Antimicrob Chemother; 2005 Oct; 56(4):745-55. PubMed ID: 16135526
[TBL] [Abstract][Full Text] [Related]
12. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.
Galgiani JN; Catanzaro A; Cloud GA; Johnson RH; Williams PL; Mirels LF; Nassar F; Lutz JE; Stevens DA; Sharkey PK; Singh VR; Larsen RA; Delgado KL; Flanigan C; Rinaldi MG
Ann Intern Med; 2000 Nov; 133(9):676-86. PubMed ID: 11074900
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group.
Catanzaro A; Galgiani JN; Levine BE; Sharkey-Mathis PK; Fierer J; Stevens DA; Chapman SW; Cloud G
Am J Med; 1995 Mar; 98(3):249-56. PubMed ID: 7872341
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
Felton TW; Baxter C; Moore CB; Roberts SA; Hope WW; Denning DW
Clin Infect Dis; 2010 Dec; 51(12):1383-91. PubMed ID: 21054179
[TBL] [Abstract][Full Text] [Related]
15. Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group.
Graybill JR; Stevens DA; Galgiani JN; Dismukes WE; Cloud GA
Am J Med; 1990 Sep; 89(3):282-90. PubMed ID: 2168126
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole.
Prabhu RM; Bonnell M; Currier BL; Orenstein R
Clin Infect Dis; 2004 Oct; 39(7):e74-7. PubMed ID: 15472837
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.
Vazquez JA; Skiest DJ; Tissot-Dupont H; Lennox JL; Boparai N; Isaacs R
HIV Clin Trials; 2007; 8(2):86-97. PubMed ID: 17507324
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of relapsing disseminated coccidioidomycosis with cutaneous involvement with posaconazole.
Wollina U; Hansel G; Vennewald I; Schönlebe J; Tintelnot K; Seibold M; Kittner T
J Dtsch Dermatol Ges; 2009 Jan; 7(1):46-9. PubMed ID: 18759738
[TBL] [Abstract][Full Text] [Related]
19. Salvage treatment of histoplasmosis with posaconazole.
Restrepo A; Tobón A; Clark B; Graham DR; Corcoran G; Bradsher RW; Goldman M; Pankey G; Moore T; Negroni R; Graybill JR
J Infect; 2007 Apr; 54(4):319-27. PubMed ID: 16824608
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.
Skiest DJ; Vazquez JA; Anstead GM; Graybill JR; Reynes J; Ward D; Hare R; Boparai N; Isaacs R
Clin Infect Dis; 2007 Feb; 44(4):607-14. PubMed ID: 17243069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
